Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Almac
 More »

  • Fluorescence Lifetime Assays
    ... By employing 9AA-labeled peptide and protein substrates, the FLEXYTE(tm) assay platform (Almac Group) has been configured for a number of important drug targets including ...
    5-15-2013
  • Scaling Up Peptide Drugs
    ... phase become increasingly important. [Almac] As growth in the GMP peptides business ... Hay, Ph.D., senior group leader at Almac. "The complexity of the design of peptide ...
    4-1-2013
  • Choosing the Right CMO
    ... To address this Almac builds "value" into its service offering by integrating development, clinical, and commercial requirements to save time and cost and to mitigate risk. Dr. ...
    2-15-2013
  • People in the News
    Charlie Morris joined Almac Clinical Technologies as vp of new products and services...The Vaccine and Gene Therapy Institute of Florida added Ted M. Ross, Ph.D. , as program ...
    1-15-2013
  • Amgen Gets License to Use DSM's XD Cell Culture Patents
    That same month, DSM Pharmaceutical Products inked a collaboration agreement with the Almac Group in the field of biocatalysis to provide sustainable manufacturing services to the ...
    1-15-2013
  • Almac Builds New Formulation Development Facility
    Almac has created a new non-GMP formulation development facility and two new analytical ... The new non-GMP formulation development facility, according to Almac, will offer clients ...
    1-14-2013
  • VTU Strikes Another Yeast Expression Deal
    The collaboration combined VTU's P. pastoris expertise and AOX1 promoter technology with DNA2.0's gene design technology for translation. Also, in June, Almac and VTU teamed up to ...
    11-26-2012
  • Monday's News in a Nutshell
    DSM Pharmaceutical Products and Almac Group inked a deal through which the firms will be ... Almac will have access to DSM's experience in commercial manufacturing bioprocesses, and ...
    10-9-2012
  • BioEurope Spring Day 2
    Almac, Northern Ireland's leading biotech, celebrated St Patrick's Day with the 'topping ... VP Business Development Philip Diamond was looking after the Almac stand at the BioEurope ...
    8-13-2012
  • BIO-Europe 2009 Day 3
    On the last point Almac Group just launched its site-specific PEGylation technology. ... with conventional PEGylation (and the Almac team showed me some nice data on this). ...
    8-9-2012
  • Changing Landscape for Contract Manufacturers
    The experts we interviewed are Kenneth F. Ball , senior manager, Pfizer CentreSource; Denis Geffroy , vp for business development, Almac; Darren Head , president and CEO, Cytovance ...
    7-1-2012
  • Getting to the Crux of Epigenetic Targets
    Effective Drug Discovery Necessitates New Tools and Technologies that Can Get the Job Done For many disease areas including oncology, autoimmune/inflammatory diseases, metabolic ...
    7-1-2012
  • Almac, VTU to Offer Site-Specific Modified Proteins Expressed...
    Almac and VTU Technology are partnering to provide joint services for the expression of ... Almac says its technology can be applied to engineered and bispecific proteins and protein ...
    6-11-2012
  • Affymetrix to Distribute Almac's Expression-Profiling Array for...
    Affymetrix negotiated exclusive distribution rights to Almac Group's Xcel(tm) array microarray, which has been developed for biomarker discovery applications in multiple ...
    3-29-2012
  • Scil, Almac Separately Report New Contract Manufacturing Deals
    Scil Proteins and Almac separately announced new contract manufacturing agreements. Scil's ... activator to Scil Proteins in 2008. Almac will manufacture MGB-BP3, MGB Biopharma's ...
    1-17-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll